Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
|Size (employees)||25 (est)|
Net income (Q2, 2018)
EBIT (Q2, 2018)
Market capitalization (20-Sep-2018)
Closing stock price (20-Sep-2018)
Corbus Pharmaceuticals has 3.7k Twitter Followers. The number of followers has increased 4.7% month over month and increased 20.6% quarter over quarter
Corbus Pharmaceuticals has 27.95k Facebook Likes. The number of likes has increased 1.3% month over month and increased 4.3% quarter over quarter